The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?

This publication has been discontinued on December 21, 2011.

Introduction

Abstract

In This Issue.

Dyslipidemia is a key independent risk factor for cardiovascular disease (CVD); CVD is the largest therapeutic segment of the world pharmaceutical market, and treatment of dyslipidemia represents a major sector of the CVD market. This report provides an overview of the condition, its role in CVD, and its prevalence. We discuss dyslipidemia treatments, with a focus on the statins as the dominant treatment choice worldwide. We review key patent expiries, including the imminent U.S. expiries of pravastatin (Bristol-Myers Squibb's Pravachol) and simvastatin (Merck & Co.'s Zocor) and the expected 2011 patent expiry of the best-selling statin, atorvastatin (Pfizer's Lipitor). In addition, we discuss emerging agents in this market, highlighting the effect generic agents may have on their adoption, or the effect these new agents may have on generics erosion of the market. Finally, we present our expectations for the market throughout our 2004-2014 forecast period.

Table of Contents

Statins and the Cardiovascular Market

Overview of Dyslipidemia

• Lipoproteins in the Blood
• Dyslipidemia and Cardiovascular Disease
• Prevalence of Dyslipidemia

Current Treatments

• Statins
• Fibrates
• Cholesterol Modulators
  • Bile Acid Sequestrants
  • Nicotinic Acid (Niacin)
  • Cholesterol Absorption Inhibitors
• Combination Products

Current Market Status

• United States
• Europe
• Japan

Key Patent Expiries

Agents in Development

• PPAR Agonists
• Cholesterol Modulators
  • CETP Inhibitors
  • ACAT Inhibitors
  • Nicotinic Acid Antagonists
  • Squalene Synthetase Inhibitors
• Combination Products
• Lp-PLA2 Inhibitor
• Statins

Market Outlook

• United States
• Europe
• Japan

Related Reports